BiotechTube
Aqua Medical

Aqua Medical

Irvine, United States· Est.
aquaendoscopy.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.7M

Overview

Aqua Medical is a private, pre-revenue medical device company founded in 2018 and headquartered in Irvine, California. The company is developing a disruptive radiofrequency vapor ablation (RFVA) platform delivered endoscopically, initially targeting the enormous unmet need in type 2 diabetes management. Its lead program aims to offer a non-surgical, outpatient procedure that could help patients achieve better HbA1c control and potentially reduce long-term healthcare costs. The technology is also positioned as a platform with potential applications across other gastrointestinal diseases.

Metabolic DiseaseGastroenterology

Technology Platform

Radio Frequency Vapor Ablation (RFVA) system: a generator that creates heated water vapor delivered via through-the-endoscope catheters for controlled tissue ablation in the GI tract.

Funding History

3
Total raised:$5.7M
Grant$400K
Seed$2.8M
Seed$2.5M

Opportunities

The massive and growing global epidemic of type 2 diabetes represents a multi-billion dollar market with a high unmet need for durable, non-pharmacologic interventions.
Successful clinical validation could position the procedure as a standard of care between failed drug therapy and invasive bariatric surgery.
The platform technology also allows for expansion into other lucrative GI disease markets.

Risk Factors

High clinical and regulatory risk associated with proving the safety and efficacy of a novel ablation mechanism for metabolic disease.
Significant commercialization risk includes establishing physician adoption, procedural reimbursement, and competing against highly effective and evolving pharmaceutical therapies like GLP-1 agonists.

Competitive Landscape

Aqua Medical competes in the emerging space of endoscopic metabolic therapy. Direct competitors include companies like Fractyl Health (Revita DMR). It also faces indirect competition from the entire diabetes drug market (especially advanced GLP-1/GIP therapies) and from bariatric surgery. Its platform approach may give it an edge in cost and versatility against single-indication devices.

More companies in Drug Delivery & Formulation →More companies in United States →